Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Silexion Therapeutics Corp (SLXN) had Consolidated Net Income/Loss of $-3.26M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-3.26M |
|
-- |
|
-- |
|
$3.29M |
|
$-3.29M |
|
$0.03M |
|
$-3.26M |
|
$-3.26M |
|
$-3.26M |
|
$-3.26M |
|
|
Consolidated Net Income/Loss |
$-3.26M |
$-3.26M |
|
$-3.29M |
|
$-3.29M |
|
1.13M |
|
1.13M |
|
$-2.88 |
|
$-2.88 |
|
| Balance Sheet Financials | |
$11.05M |
|
$0.03M |
|
$0.56M |
|
$11.61M |
|
$2.79M |
|
$1.54M |
|
$1.85M |
|
$4.64M |
|
$6.98M |
|
$6.98M |
|
$6.98M |
|
3.13M |
|
| Cash Flow Statement Financials | |
$-7.80M |
|
$-0.01M |
|
$15.86M |
|
$1.27M |
|
$9.32M |
|
$8.05M |
|
$0.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.97 |
|
-- |
|
-- |
|
0.18 |
|
0.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.81M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-46.75% |
|
-46.75% |
|
-28.09% |
|
-38.30% |
|
$2.23 |
|
$-6.89 |
|
$-6.89 |
|